License to Work: A National Study of Burdens from Occupational Licensing 3rd edition

For millions of lower-income Americans, state licensing laws make finding work or opening a small business harder and more expensive—if not outright impossible. These laws force would-be workers in fields like barbering, landscaping, interior design and many more to get a government permission slip—an occupational license—before they can legally work. To do so, they often must complete costly training, pass exams, pay fees and more.This third edition of License to Work finds licensing laws like these are widespread: In all, we identified more than 2,700 licenses across the 50 states and the District of Columbia. We found the burdens these licenses impose are steep: nearly a year of required education and experience, at least one exam, and $295 in fees, on average. Licensing laws might be worth it if they improved services or made the public safer, but evidence suggests they often don't. But we also found some good news: Since 2017, states have eliminated more licenses than they have created, and nearly 20% of licenses have become less burdensome. Policymakers can open jobs to more Americans and support new businesses by continuing reforms like these

Policing for profit: The abuse of civil asset forfeiture, 3rd edition

Most states and the federal government have laws allowing police and prosecutors to seize and permanently keep Americans’ cash, cars, homes and other property suspected of being involved in a crime—without regard to the owners’ guilt or innocence. This is civil forfeiture, and it is rampant nationwide, with local, state and federal agencies using it to collectively forfeit billions of dollars each year. Many of these billions go directly to law enforcement, including the same police and prosecutors who seize and forfeit property. This third edition of Policing for Profit presents the largest collection of state and federal forfeiture data yet assembled and provides updated grades of state and federal civil forfeiture laws. Key findings include: - Many jurisdictions fail to provide a full accounting of forfeiture activity, so any estimate of forfeiture’s scope will undercount. Still, by any measure, forfeiture activity is extensive nationwide, sending billions of dollars to government coffers; - State and federal laws make forfeiture easy and profitable for law enforcement; - New research shows eliminating civil forfeiture does not decrease crime; - Federal equitable sharing creates a giant loophole; - Forfeiture isn’t targeting kingpins and ordinary people can’t fight bac

License to Work: A National Study of Burdens from Occupational Licensing

The right to earn an honest living has always been a fundamental American right. But in recent decades, this right has become increasingly circumscribed by occupational licensing laws. Occupational licensing is, put simply, government permission to work in a particular field. In the 1950s, about one in 20 American workers needed an occupational license before they could work in the occupation of their choice. Today, that figure stands at about one in four. Securing an occupational license may require education or experience, exams, fees, and more, and working without one can mean fines or even jail time. The growth of occupational licensing and the barriers it presents to job seekers have attracted mounting bipartisan concern. Policymakers, scholars and opinion leaders left, right and center are increasingly recognizing that licensing comes with high costs—fewer job opportunities and steeper prices—and does little to improve quality or protect consumers. This second edition of License to Work examines both the scope and the specific burdens of occupational licensing, documenting licensing requirements for 102 lower-income occupations across all 50 states and the District of Columbia. It finds that these barriers to entry can pose substantial difficulties for job seekers and would-be entrepreneurs

License to Work: A National Study of Burdens from Occupational Licensing

MMSID: 9912685792950642

Real-world performance of SARS-Cov-2 serology tests in the United States, 2020.

BackgroundReal-world performance of COVID-19 diagnostic tests under Emergency Use Authorization (EUA) must be assessed. We describe overall trends in the performance of serology tests in the context of real-world implementation.MethodsSix health systems estimated the odds of seropositivity and positive percent agreement (PPA) of serology test among people with confirmed SARS-CoV-2 infection by molecular test. In each dataset, we present the odds ratio and PPA, overall and by key clinical, demographic, and practice parameters.ResultsA total of 15,615 people were observed to have at least one serology test 14-90 days after a positive molecular test for SARS-CoV-2. We observed higher PPA in Hispanic (PPA range: 79-96%) compared to non-Hispanic (60-89%) patients; in those presenting with at least one COVID-19 related symptom (69-93%) as compared to no such symptoms (63-91%); and in inpatient (70-97%) and emergency department (93-99%) compared to outpatient (63-92%) settings across datasets. PPA was highest in those with diabetes (75-94%) and kidney disease (83-95%); and lowest in those with auto-immune conditions or who are immunocompromised (56-93%). The odds ratios (OR) for seropositivity were higher in Hispanics compared to non-Hispanics (OR range: 2.59-3.86), patients with diabetes (1.49-1.56), and obesity (1.63-2.23); and lower in those with immunocompromised or autoimmune conditions (0.25-0.70), as compared to those without those comorbidities. In a subset of three datasets with robust information on serology test name, seven tests were used, two of which were used in multiple settings and met the EUA requirement of PPA ≥87%. Tests performed similarly across datasets.ConclusionAlthough the EUA requirement was not consistently met, more investigation is needed to understand how serology and molecular tests are used, including indication and protocol fidelity. Improved data interoperability of test and clinical/demographic data are needed to enable rapid assessment of the real-world performance of in vitro diagnostic tests

Microplastic in the water cycle : sampling, sample preparation, analyses, occurrence and assessment

Gedruckt erschienen im Universitätsverlag der TU Berlin, ISBN 978-3-7983-3162-4Das interdisziplinäre Forschungsprojekt MiWa widmete sich grundlegenden Fragestellungen zur Analytik und Wirkung von Mikroplastik-Partikeln im Wasserkreislauf. Es wurden Methoden der Umweltprobennahme, der Probenaufbereitung und verschiedene Detektionsverfahren zur Charakterisierung und Quantifizierung von Mikroplastik intensiv untersucht, miteinander verglichen und weiterentwickelt. Öko- und humantoxikologische Untersuchungen dienten dem Zweck, die potenziell von Mikroplastik ausgehende Gefährdung für die aquatische Umwelt und den Menschen zu analysieren und zu bewerten. Eine Harmonisierung und Standardisierung von Methoden der Probennahme, Probenaufbereitung und Mikroplastik-Detektion sind trotz der erheblichen Fortschritte derzeit nur teilweise möglich. Die ökotoxikologischen Studien zeigen zwar die Aufnahme von Mikroplastik-Partikeln durch einige Organismen, jedoch konnte bisher keine schädigende Wirkung nachgewiesen werden. Dabei wurden für eine Auswahl aquatischer Modellspezies sowohl Szenarien direkter als auch indirekter Exposition innerhalb einer Nahrungskette betrachtet. Interaktionen mit menschlichen Modellzellen wurden bislang nur bei Mikroplastik-Partikeln mit Größen weit unterhalb von 1 µm (also Nanoplastik) beobachtet. Eine umfassende Bewertung ist bislang nicht möglich.The interdisciplinary research project MiWa focused on principle knowledge gaps of analytical detection and effects of microplastic in fresh water cycles. Methods for environmental sampling, sample preparation and different analytical identification and quantification were intensively investigated, compared and further developed. Toxicological studies were conducted to assess potential risks of microplastic particles towards the environment and human health. Harmonization and standardization are still only partially possible despite various improvements. The eco-toxicological experiments confirmed the intake of microplastic particles by different organisms but no hazardous effects could be found. Both direct ingestions and indirect exposition within food webs were tested. Interactions with exemplary human cells were only observed for particle sizes far below 1 µm (thus nanoplastic). An assessment is currently only possible to a limited extent.BMBF, 02WRS1378, Mikroplastik im Wasserkreislauf (MiWa

Real-world utilization of SARS-CoV-2 serological testing in RNA positive patients across the United States.

BackgroundAs diagnostic tests for COVID-19 were broadly deployed under Emergency Use Authorization, there emerged a need to understand the real-world utilization and performance of serological testing across the United States.MethodsSix health systems contributed electronic health records and/or claims data, jointly developed a master protocol, and used it to execute the analysis in parallel. We used descriptive statistics to examine demographic, clinical, and geographic characteristics of serology testing among patients with RNA positive for SARS-CoV-2.ResultsAcross datasets, we observed 930,669 individuals with positive RNA for SARS-CoV-2. Of these, 35,806 (4%) were serotested within 90 days; 15% of which occurred <14 days from the RNA positive test. The proportion of people with a history of cardiovascular disease, obesity, chronic lung, or kidney disease; or presenting with shortness of breath or pneumonia appeared higher among those serotested compared to those who were not. Even in a population of people with active infection, race/ethnicity data were largely missing (>30%) in some datasets-limiting our ability to examine differences in serological testing by race. In datasets where race/ethnicity information was available, we observed a greater distribution of White individuals among those serotested; however, the time between RNA and serology tests appeared shorter in Black compared to White individuals. Test manufacturer data was available in half of the datasets contributing to the analysis.ConclusionOur results inform the underlying context of serotesting during the first year of the COVID-19 pandemic and differences observed between claims and EHR data sources-a critical first step to understanding the real-world accuracy of serological tests. Incomplete reporting of race/ethnicity data and a limited ability to link test manufacturer data, lab results, and clinical data challenge the ability to assess the real-world performance of SARS-CoV-2 tests in different contexts and the overall U.S. response to current and future disease pandemics